Figure 6.
In vivo antitumor efficacy of MAGE-A1 specific HLA-A2, -A3, and -C7 restricted TCRs
NSG mice engrafted with 2 × 106 U266 cells were i.v. injected with 5 × 106 TCR-T cells 14 days after tumor injection. T cells were transduced with the 4F7 (MAGE-A1 KVL/A2) TCR, 3H4 (MAGE-A1 SLF/A3) TCR, 10C1 (MAGE-A1 VRF/C7) TCR, or CMV (pp65 NLV/A2) TCR and enriched for mTCRβ expression by MACS. Tumor growth was visualized by bioluminescence imaging 1–2 times per week. (A) Mean of average tumor outgrowth of the dorsal and ventral side of 6 × 4F7 TCR-T cell (black), 6 × 10C1 TCR-T cell (red), and 4 × CMV TCR-T cell (white) treated mice. (B) Tumor outgrowth of representative individual 4F7 TCR-T cell, 10C1 TCR-T cell, and CMV TCR-T cell treated mice measured on the ventral side. (C) Mean of average tumor outgrowth of the dorsal and ventral side of 5 × 3H4 TCR-T cell (red) and 4 × CMV TCR-T cell (white). (D) Kaplan-Meier plot of 3H4 TCR-T cell and CMV TCR-T cell treated mice.